What are the current hypertension treatment guidelines?

Hypertension Treatment Guidelines

For most adults with confirmed hypertension (BP ≥140/90 mmHg), initiate combination therapy with a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic, preferably as a single-pill combination, targeting systolic BP 120-129 mmHg if well tolerated. 1

Diagnosis and Confirmation

Blood Pressure Measurement:

• Use validated automated upper arm cuff devices with appropriate cuff size 2
• Measure BP in both arms simultaneously at first visit; use the arm with higher readings for subsequent measurements 2
• Hypertension is defined as office BP ≥140/90 mmHg, confirmed with home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg 2
• Remeasure over 2-3 office visits before confirming diagnosis 2

Important Caveat: The 2024 ESC guidelines define hypertension at a lower threshold (≥130/80 mmHg) compared to the 2020 ISH guidelines (≥140/90 mmHg), though both agree on treatment initiation criteria for most patients 1, 2. The newer ESC guideline represents a shift toward earlier intervention.

Treatment Initiation

Immediate Drug Therapy Indicated For: 2

• Grade 2 hypertension (BP ≥160/100 mmHg) - all patients
• Grade 1 hypertension (BP 140-159/90-99 mmHg) with:
  • Cardiovascular disease
  • Chronic kidney disease
  • Diabetes mellitus
  • Organ damage
  • Age 50-80 years

Delayed Drug Therapy (After 3-6 Months Lifestyle Intervention): 2

• Grade 1 hypertension in low-moderate risk patients without the above conditions
• Elevated BP (130-139/80-89 mmHg) with high cardiovascular risk (≥10% over 10 years) after 3 months of lifestyle measures 1

First-Line Pharmacotherapy

Preferred Initial Combination Therapy: 1, 3

• Non-Black patients: ACE inhibitor or ARB + dihydropyridine calcium channel blocker OR thiazide/thiazide-like diuretic
• Black patients: ARB + dihydropyridine calcium channel blocker OR dihydropyridine calcium channel blocker + thiazide/thiazide-like diuretic

Single-pill combinations are strongly preferred over separate pills to improve adherence 1, 3

Exceptions to Combination Therapy (Consider Monotherapy): 2

• Age >80 years
• Frail patients
• Low-risk Grade 1 hypertension
• Symptomatic orthostatic hypotension

Stepwise Escalation Algorithm

Step 1: Low-dose RAS blocker (ACE inhibitor or ARB) + calcium channel blocker or diuretic 2

Step 2: Increase to full doses 2

Step 3: Add third agent to create triple therapy (RAS blocker + calcium channel blocker + thiazide/thiazide-like diuretic), preferably as single-pill combination 1

Step 4: Add spironolactone; if not tolerated or contraindicated, use amiloride, doxazosin, eplerenone, clonidine, or beta-blocker 2

Critical Pitfall: Never combine two RAS blockers (ACE inhibitor + ARB) - this is explicitly not recommended due to increased adverse events without additional benefit 1

Blood Pressure Targets

Primary Target: 1

• Systolic BP 120-129 mmHg in most adults if well tolerated
• This represents the most recent (2024) and aggressive target from the ESC guidelines

Alternative Targets When Intensive Target Not Achievable: 3

• General population: <140/90 mmHg (WHO 2022)
• Patients with known CVD: <130 mmHg systolic (WHO 2022)
• High-risk patients (high CVD risk, diabetes, CKD): <130 mmHg systolic (WHO 2022)

Special Populations: 2, 1

• Elderly and frail patients: Individualize based on tolerability; use "as low as reasonably achievable" (ALARA) principle if intensive targets poorly tolerated
• Achieve target BP within 3 months of treatment initiation 2

Important Nuance: The 2024 ESC guidelines (120-129 mmHg) are more aggressive than WHO 2022 guidelines (<140/90 mmHg general, <130 mmHg high-risk), reflecting evolving evidence from intensive BP trials. The ESC target prioritizes cardiovascular event reduction in those who can tolerate it 1, 3.

Beta-Blockers

Not recommended as first-line monotherapy 1

Appropriate Use: Combine with other major BP-lowering drug classes when compelling indications exist: 1

• Angina pectoris
• Post-myocardial infarction
• Heart failure with reduced ejection fraction
• Heart rate control requirements

Lifestyle Modifications

All patients should implement: 1

• Mediterranean or DASH diet
• Sodium restriction
• Target BMI 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women)
• Aerobic exercise (150 minutes/week moderate intensity or 75 minutes/week vigorous) plus resistance training 2-3 times/week
• Alcohol consumption <100 g/week pure alcohol (preferably avoid completely)
• Restrict free sugar to <10% of energy intake; avoid sugar-sweetened beverages
• Complete tobacco cessation with referral to cessation programs

Monitoring and Follow-Up

Frequency: 3

• Monthly follow-up after initiation or medication changes until target achieved
• Every 3-5 months once BP controlled

Adherence Assessment: 2

• Check medication adherence at every visit
• Single-pill combinations significantly improve adherence compared to multiple separate pills

Timing of Medication: 1

• Take medications at the most convenient time for the patient to establish habitual pattern
• No specific evidence favoring morning versus evening dosing for most patients

Referral Criteria: 2

• BP remains uncontrolled despite appropriate therapy
• Suspected secondary hypertension
• Need for specialized expertise

Key Practice Pitfalls to Avoid

1. Do not use monotherapy as initial treatment for most patients with confirmed hypertension ≥140/90 mmHg - combination therapy is superior 1
2. Do not prescribe multiple separate pills when single-pill combinations are available - adherence suffers significantly 1, 3
3. Do not combine ACE inhibitor + ARB - increased harm without benefit 1
4. Do not use beta-blockers as first-line monotherapy unless compelling indication exists 1
5. Do not delay treatment in Grade 2 hypertension or high-risk Grade 1 hypertension waiting for lifestyle modifications alone 2
6. Do not discontinue treatment even beyond age 85 if well tolerated - maintain lifelong therapy 1